Merck Unsure Whether Vytorin, Zetia Can Cushion Fosamax’s Patent Loss
Executive Summary
Sales of Merck's new and inline products will drive growth in 2008 as the company turns to drugs like Januvia, Singulair, Cozaar/Hyzaar and vaccines to cushion the blow from the loss of exclusivity for Fosamax, Chief Financial Officer Peter Kellogg reported during the company's year-end financial call Jan. 30
You may also be interested in...
Vytorin/Zetia Rx Decline Prompts Schering-Plough To Issue Monthly Updates
Schering-Plough says it will soon start providing monthly updates on prescription rates for its two cholesterol drugs Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe) to help ease the minds of anxious investors
Vytorin/Zetia Rx Decline Prompts Schering-Plough To Issue Monthly Updates
Schering-Plough says it will soon start providing monthly updates on prescription rates for its two cholesterol drugs Vytorin (ezetimibe/simvastatin) and Zetia (ezetimibe) to help ease the minds of anxious investors
FDA To Review Vytorin Data: ENHANCEd Label To Follow?
FDA expects to complete a review of data from the ENHANCE study for Merck and Schering-Plough's Vytorin within nine months, Office of New Drugs Director John Jenkins announced Jan. 25